A Lehigh Valley biopharmaceutical company has announced that it is investing in a $15 million expansion of its operations.
US Specialty Formulations, which was founded in 2013 by Dr. Kyle Flanigan, CEO, and Dr. Garry Morefield, COO, is now entering the next stage of what the co-founders described as a multi-phase expansion.
The company is best known for pioneering QYNDR, an oral vaccine platform and the first self-administered drinkable vaccine, which completed a successful Phase I clinical trial in 2023.
Flanigan and Morefield hand-built their first certified clean room at Ben Franklin Technical Incubator in Bethlehem.
With $4.7M already secured, the partners said the expansion will bring new facility clean room suites and state-of-the-art automated packaging and product inspection equipment. This expansion will more than double USSF’s clean room production capacity and will enable the company to undertake substantially larger projects supporting growth for new and current clients.
The expansion is expected to significantly boost the local economy through job creation and increased revenue for the region. USSF hopes to employ more than 100 people to support the Allentown facility.
“This expansion is a transformative step for USSF,” said Flanigan. “By investing in cutting-edge technology and streamlining our manufacturing processes, we are raising the bar for ourselves and reaffirming our commitment to delivering innovative pharmaceutical solutions that reduce the risk profile of new drug development or contract manufacturing and ultimately improve patient lives. This expansion empowers our dedicated team to serve our partners and clients worldwide more effectively.”
USSF offers a range of services, including drug research and development, contract manufacturing, private label formulations and packaging and small molecule pharmaceuticals.
Read moreTags: contract manufacturing